LGND vs OMAB

For growth investors, Ligand Pharmaceuticals Incorporated (LGND) is the stronger pick with 27.

3% revenue growth year-over-year, versus 5. 9% for Grupo Aeroportuario del Centro Norte, S. A. B. de C. V. (OMAB). Grupo Aeroportuario del Centro Norte, S. A. B. de C. V. (OMAB) offers the better valuation at 16. 7x trailing P/E (0. 8x forward), making it the more compelling value choice. Analysts rate Ligand Pharmaceuticals Incorporated (LGND) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Grupo Aeroportuario del Centro Norte, S.

A. B. de C. V. is actually cheaper at 0. 8x.

Over the past 5 years, Grupo Aeroportuario del Centro Norte, S.

A. B. de C. V. (OMAB) delivered a total return of +157. 3%, compared to +83. 9% for Ligand Pharmaceuticals Incorporated (LGND). Over 10 years, the gap is even starker: OMAB returned +189. 2% versus LGND's +95. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Grupo Aeroportuario del Centro Norte, S.

A. B. de C. V. (OMAB) is the lower-risk stock at 0. 62β versus Ligand Pharmaceuticals Incorporated's 0. 99β — meaning LGND is approximately 59% more volatile than OMAB relative to the S&P 500. On balance sheet safety, Ligand Pharmaceuticals Incorporated (LGND) carries a lower debt/equity ratio of 1% versus 119% for Grupo Aeroportuario del Centro Norte, S. A. B. de C. V. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ligand Pharmaceuticals Incorporated (LGND) is pulling ahead at 27.

3% versus 5. 9% for Grupo Aeroportuario del Centro Norte, S. A. B. de C. V. (OMAB). On earnings-per-share growth, the picture is similar: Grupo Aeroportuario del Centro Norte, S. A. B. de C. V. grew EPS 8. 4% year-over-year, compared to -107. 5% for Ligand Pharmaceuticals Incorporated. Over a 3-year CAGR, OMAB leads at 10. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Grupo Aeroportuario del Centro Norte, S.

A. B. de C. V. (OMAB) is the more profitable company, earning 33. 5% net margin versus -2. 4% for Ligand Pharmaceuticals Incorporated — meaning it keeps 33. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OMAB leads at 56. 0% versus -13. 5% for LGND. At the gross margin level — before operating expenses — LGND leads at 93. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Grupo Aeroportuario del Centro Norte, S.

A. B. de C. V. (OMAB) trades at 0. 8x forward P/E versus 26. 1x for Ligand Pharmaceuticals Incorporated — 25. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OMAB: 19. 1% to $127. 00.

In this comparison, OMAB (5.

0% yield) pays a dividend. LGND does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Grupo Aeroportuario del Centro Norte, S.

A. B. de C. V. (OMAB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 62), 5. 0% yield, +189. 2% 10Y return). Both have compounded well over 10 years (OMAB: +189. 2%, LGND: +95. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (LGND (Healthcare) and OMAB (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: LGND is a small-cap high-growth stock; OMAB is a small-cap deep-value stock. OMAB pays a dividend while LGND does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.